Anti-CD47 Antibody Eliminates Bone Tumors in Rats

Publication date: Available online 13 September 2019Source: Saudi Journal of Biological SciencesAuthor(s): Shiqiang Fang, Hainan Yin, Zhen Song, Ruixin Li, Xuesheng Xie, Zengquan GuAbstractBone tumor is a rare heterogeneous malignancy. Osteosarcoma is the most common bone tumor with no apparent underlying pathogenesis, and its peak incidence often occurs during puberty. The intensive application of chemotherapy rarely alters the poor prognosis of the patients in advanced stage. Despite intensive chemotherapy in clinical practice, patients still suffer from the poor prognosis, or even progression of bone tumor. We identified integrin-associated protein (IAP) Cluster of Differentiation 47 (CD47) as a target for monoclonal antibody, and use anti-CD47 antibody to block its expression in bone tumors. CD47 was highly expressed in the bone tumor rats when comparing to the healthy rats. Likewise, Western blotting assay revealed a higher protein expression of CD47 in the bone tumor cells when compared to the normal osteoblasts. Further studies have shown the association between the mRNA expression of CD47 and the disordered bone tumors development and decreased rate of overall survival of diseased rats. In addition, blocking the CD47 monoclonal antibody has been shown to drive macrophages to engulf bone tumor cells in vitro and thus inhibiting tumor metastasis in rats. Taken together, the results of this study suggested that CD47 is a key regulator of bone tumor cell metastasis and th...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research

Related Links:

The aim of this study was to provide a basis for the theory that the combination of conventional chemotherapy and immunotherapy would be an effective treatment for osteosarcoma. Here, the expression of programmed death ligand 1 (PD-L1) in 26 clinical osteosarcoma tissue samples collected before and after chemotherapy was analyzed. The effects of osteosarcoma cells treated with doxorubicin, a conventional chemotherapeutic agent, on the proliferation and apoptosis of CD8+ T lymphocytes were investigated in vitro. Thereafter, the effectiveness of doxorubicin combined with an anti-PD-L1 antibody as an osteosarcoma therapy was ...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Basic Studies Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Perspective Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H Abstract Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the r...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Authors: De Marinis F, Barberis M, Barbieri V, Marchianò A, Gasparini S, Migliorino MR, Romano G, Spinnato F, Vitiello F, Gridelli C Abstract INTRODUCTION: In the era of personalized cancer therapy, the sampling of adequate tumor tissue for histologic diagnosis and genomic profiling is crucial, not only at the initial diagnosis but also in the event of resistant and recurrent disease when sequential biopsies may be required to evaluate somatic mutations and histologic changes. Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from ...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
Conclusions:Using the IgG(L)-scFv format, GD2-BsAb or HER2-BsAb armed ATCs could provide a potent and economical cytotherapy platform against GD2(+) or HER2(+) tumors without the complexity of gene modification (as in chimeric antigen receptor modified T cells). At such low arming doses, where BsAb is T cell bound, where ADTC is not induced, and T cell expansion is not required for anti-tumor effect, clinical toxicity is expected to be low.DisclosuresCheung: Ymabs: Patents &Royalties.
Source: Blood - Category: Hematology Authors: Tags: 703. Adoptive Immunotherapy: Poster III Source Type: research
SummaryOsteosarcoma (OS) is the most common primary aggressive and malignant bone tumor. Newly diagnostic OS patients benefit from the standard therapy including surgical resection plus radiotherapy and neoadjuvant chemotherapy (MAP chemotherapy: high-dose methotrexate, doxorubicin and cisplatin). However, tumor recurrence and metastasis give rise to a sharp decline of the 5-year overall survival rate in OS patients. Little improvement has been made for decades, urging the development of more effective therapeutic approaches. ErbB receptor family including EGFR, HER2, HER3 and HER4, being important to the activation of PI3...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
This study concerns a cohort of unselected patients aged
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Dr. Vincent Ng is an orthopaedic oncologist with the University of Maryland Greenebaum Comprehensive Cancer Center and an Assistant Professor or Orthopaedics with the University of Maryland School of Medicine.  Dr. Ng specializes in treating bone cancer and soft tissue sarcoma.  Below he answers common questions about orthopaedic oncology. What is an orthopaedic oncologist? How do they differ from surgical oncologists? “An orthopaedic oncologist specializes in bone and soft tissue tumors.  I treat any adult or pediatric patient with any bone or soft tissue tumor/lesion/mass, whether benign or malignan...
Source: Life in a Medical Center - Category: Universities & Medical Training Authors: Tags: Cancer Doctors bone cancer oncology orthopedics Source Type: blogs
More News: Biology | Bone Cancers | Cancer & Oncology | Chemotherapy | Immunotherapy | Middle East Health | Osteosarcoma | Saudi Arabia Health | Study